GEP-NETGastroenteropancreatic Neuroendocrine tumor
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
In this analysis, a significant increase of Cg A concentration was observed in patients with GEP-NET, but a significant difference in Cg A levels was not observed in relation to the primary localization of the GEP-NET.
At diagnosis of GEP-NET patients, an indicative predictor of shorter survival is a Cg A concentration in excess of three times the upper limit of the normal [88].
Data from 42 patients diagnosed with GEP-NET who were treated and followed up at our Training and Research Hospital from August 2011 to December 2015 were retrospectively evaluated.
Although gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are known as rare neoplasms, their prevalence has recently increased due to advanced diagnostic methods and increased awareness of the disorder (3).
We excluded patients with diagnosis of poorly differentiated endocrine carcinoma (PDEC) GEP-NET according to WHO 2000 classification, with diagnosis of NEC according to WHO 2010 classification after revision, or without material for revision or immunostaining.
A total of 45 patients with GEP-NET diffuse liver metastases, who received at least two courses of drug therapy after resection of the primary tumor between February 2012 and June 2015, were retrospectively collected for this study.
Healthcare company Advanced Accelerator Applications announced on Friday that it has received US Food and Drug Administration approval for Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
However, cross-sectional parameters, such as computed tomography (CT) and magnetic resonance imaging (MRI), play an imperative role in the accurate diagnosis and management of GEP-NETs. The details provided by these modalities help provide options for better surgical planning, further characterisation of disease extent and presence of metastasis.
Carrato, "Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)," Clinical and Translational Oncology, vol.
The basic principle of applying treatment with radiopharmaceuticals in GEP-NETs relies on the use of high-energy [beta]-emitters to generate radiation-induced DNA damage in targeted somatostatin receptor (sstr) expressing GEP-NETs [2, 88].